Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Sonnet Biotherapeutics Holdings Inc (SONN)

Sonnet Biotherapeutics Holdings Inc (SONN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview ACCESSWIRE - Tue Oct 31, 2023

PRINCETON, NJ / ACCESSWIRE / October 31, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, provided a fiscal year...

SONN : 1.8600 (+5.08%)
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering ACCESSWIRE - Wed Oct 25, 2023

PRINCETON, NJ / ACCESSWIRE / October 25, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("we," "us," "our," "Sonnet" or the "Company"), a clinical-stage company developing innovative targeted...

SONN : 1.8600 (+5.08%)
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting ACCESSWIRE - Tue Oct 17, 2023

PRINCETON, NJ / ACCESSWIRE / October 17, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs,...

SONN : 1.8600 (+5.08%)
Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology ACCESSWIRE - Wed Sep 20, 2023

PRINCETON, NJ / ACCESSWIRE / September 20, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced data from two radiolabeling...

SONN : 1.8600 (+5.08%)
Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy AccessWire - Fri Jul 22, 2022

PRINCETON, NJ / ACCESSWIRE / July 22, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a Phase 1b/2a...

SONN : 1.8600 (+5.08%)
Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers AccessWire - Thu Jul 21, 2022

PRINCETON, NJ / ACCESSWIRE / July 21, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a second Phase...

SONN : 1.8600 (+5.08%)
Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition AccessWire - Thu Jun 9, 2022

PRINCETON, NJ / ACCESSWIRE / June 9, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, today...

SONN : 1.8600 (+5.08%)
Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum AccessWire - Thu Jun 2, 2022

PRINCETON, NJ / ACCESSWIRE / June 2, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, today...

SONN : 1.8600 (+5.08%)
Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update AccessWire - Tue May 10, 2022

- IND for SON-1010 cleared by FDA with first patient dosed in trial for advanced solid tumors - SON-080 on track to begin clinical studies by mid-2022 - Preclinical data for SON-1010, SON-1210, and SON-1410...

SONN : 1.8600 (+5.08%)
Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors AccessWire - Wed Apr 13, 2022

PRINCETON, NJ / ACCESSWIRE / April 13, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that dosing has...

SONN : 1.8600 (+5.08%)

Barchart Exclusives

Down 12% from Highs, Should You Buy the Dip in This Dividend Aristocrat? Barchart - Wed May 1, 6:30PM CDT
This prominent paint industry player has been raising dividends for more than four decades. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot